News

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting
Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...
GEN - Genetic Engineering and Biotechnology News3d
Cutting mAb Costs and Boosting Access in Low- and Middle-Income Countries
Moving away from batch-mode production and using higher-yield cell lines are also options for mAb makers looking to reduce ...
Taiwan News3h
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Modeling data indicated that the greater predicted reduction of FeNO observed with verekitug, compared with published data for tezepelumab, is potentially driven by lower expression levels of the TSLP ...
Amgen: Imdelltra Data And Q1 Results Impress
Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...
Kalkine Media2d
Incyte : Retifanlimab Plus Chemotherapy Meets Primary Endpoint In Phase 3 SCAC Trial
Incyte Corp. (INCY) announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz)—a humanized monoclonal antibody targeting PD-1—combined with carboplatin and ...
The Manila Times5d
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
Under the terms of the royalty purchase agreement, MacroGenics received a $70 million upfront payment for the sale of its ...
PMLive2d
FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa
The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer ...
The American Journal of Managed Care2d
CARTITUDE-1 Trial Shows Unprecedented 5-Year Remission in Relapsed/Refractory Multiple Myeloma: Sundar Jagganath, MBBS
Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...